We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




DSL Acquires Oxford Bio-Innovation

By HospiMedica staff writers
Posted on 12 Nov 2001
In a move that will complement its line of fertility products, Diagnostic Systems Laboratories (DSL; Webster, TX, USA) has acquired Oxford Bio-Innovation Ltd. More...
(OBI, Oxford, UK). Terms were not disclosed.

OBI makes and markets diagnostic and research products and has a clinical testing service. Its products include kits and reagents for inhibin A, inhibin B, and activin, all of which play a role in male infertility, assessment of ovarian reserve, prediction of in vitro fertilization (IVF) outcomes, and differential diagnosis of ovarian cancer. The tests are used by clinical and research laboratories worldwide.

DSL develops and manufactures products for global clinical, research, academic, and veterinary markets and currently offers more than 190 immunoassay products. These include tests for fertility and reproduction, thyroid function, growth factors, and bone and mineral metabolism.

"The acquisition of OBI positions DSL as the exclusive global provider of diagnostic tests for the measurement of inhibins and activins,” said Gopal V. Savjani, CEO of DSL.
"DSL's strength in the field of reproductive endocrinology combined with OBI's focus and experience in the area of inhibins and activins will enable us to accelerate the development of additional products and clinical applications in this field.”




Related Links:
DSL

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
All-in-One Molecular System
AIO M160
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.